Alterations of brain network activity are observable in Alzheimer's disease (AD) together with the occurrence of mild cognitive impairment, before overt pathology. However, in humans as well in AD mouse models, identification of early biomarkers of network dysfunction is still at its beginning. We performed in vivo recordings of local field potential activity in the dentate gyrus of PS2APP mice expressing the human amyloid precursor protein (APP) Swedish mutation and the presenilin-2 (PS2) N141I. From a frequency-domain analysis, we uncovered network hyper-synchronicity as early as 3 months, when intracellular accumulation of amyloid beta was also observable. In addition, at 6 months of age, we identified network hyperactivity in the beta/gamma frequency bands, along with increased theta-beta and theta-gamma phase-amplitude cross-frequency coupling, in coincidence with the histopathological traits of the disease. Although hyperactivity and hypersynchronicity were respectively detected in mice expressing the PS2-N141I or the APP Swedish mutant alone, the increase in cross-frequency coupling specifically characterized the 6-month-old PS2APP mice, just before the surge of the cognitive decline.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neurobiolaging.2016.10.027 | DOI Listing |
J Neurosci
July 2024
Departments of Neuroscience, Genentech, Inc., South San Francisco, California 94080
Human genetics and preclinical studies have identified key contributions of TREM2 to several neurodegenerative conditions, inspiring efforts to modulate TREM2 therapeutically. Here, we characterize the activities of three TREM2 agonist antibodies in multiple mixed-sex mouse models of Alzheimer's disease (AD) pathology and remyelination. Receptor activation and downstream signaling are explored in vitro, and active dose ranges are determined in vivo based on pharmacodynamic responses from microglia.
View Article and Find Full Text PDFTheranostics
January 2024
Peripheral Neuropathy Research Center, College of Medicine, Dong-A University, Busan, Republic of Korea.
Promotion of mitophagy is considered a promising strategy for the treatment of neurodegenerative diseases including Alzheimer's disease (AD). The development of mitophagy-specific inducers with low toxicity and defined molecular mechanisms is essential for the clinical application of mitophagy-based therapy. The aim of this study was to investigate the potential of a novel small-molecule mitophagy inducer, ALT001, as a treatment for AD.
View Article and Find Full Text PDFNeuroimage Clin
September 2023
Department of Nuclear Medicine, University Hospital of Munich, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Electronic address:
Objective: In preclinical research, the use of [F]Fluorodesoxyglucose (FDG) as a biomarker for neurodegeneration may induce bias due to enhanced glucose uptake by immune cells. In this study, we sought to investigate synaptic vesicle glycoprotein 2A (SV2A) PET with [F]UCB-H as an alternative preclinical biomarker for neurodegenerative processes in two mouse models representing the pathological hallmarks of Alzheimer's disease (AD).
Methods: A total of 29 PS2APP, 20 P301S and 12 wild-type mice aged 4.
Cell Calcium
July 2023
Department of Physiology, Jiaxing University College of Medicine, Jiaxing, Zhejiang Pro, China; Department of Molecular Neurobiology, Institute of Bioorganic Chemistry RAS, Moscow, Russia; Department of Clinical Pharmacology, Sechenov First Moscow State Medical University, Moscow 119435, Russia. Electronic address:
Lia et al. [1] discovered the critical role of STIM1 ER Ca sensor in the functional decline of astrocytes in the AD-like pathology in PS2APP mice. Profound downregulation of STIM1 expression in astrocytes in the disease results in the decreased ER Ca content and severely impaired evoked as well as spontaneous astrocytic Ca signalling.
View Article and Find Full Text PDFNat Commun
March 2023
Neuroscience Institute, National Research Council (CNR), Padua, Italy.
Calcium dynamics in astrocytes represent a fundamental signal that through gliotransmitter release regulates synaptic plasticity and behaviour. Here we present a longitudinal study in the PS2APP mouse model of Alzheimer's disease (AD) linking astrocyte Ca hypoactivity to memory loss. At the onset of plaque deposition, somatosensory cortical astrocytes of AD female mice exhibit a drastic reduction of Ca signaling, closely associated with decreased endoplasmic reticulum Ca concentration and reduced expression of the Ca sensor STIM1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!